Bruker Daltonics Announces Opening of maXis™ U.S. Demonstration Facility
News Mar 06, 2009
Bruker Daltonics has announced the opening of its Massachusetts demonstration facility for the ultra-high resolution time-of-flight (UHR-TOF) maXis™ mass spectrometer, as well as several maXis installations in top-tier U.S. life-science research laboratories.
The maXis, which Bruker will exhibit at PITTCON 2009 next week in Chicago, is said to be the only high-performance mass spectrometer available that simultaneously fulfills the two previously incompatible requirements in modern mass spectrometry of ultra-high mass resolution and fast UHPLC separations.
maXis is designed to deliver the combination of exceptional mass accuracy of better than 1 ppm, ultra-high mass resolving power of 40,000 to 60,000, dynamic range over 5 orders of magnitude, high m/z capabilities, stability allowing 1.5 mDa high-resolution extracted ion chromatograms (hrEIC), as well as outstanding sensitivity, all in MS and MS/MS mode and all maintained simultaneously even when coupled to separations fast liquid chromatography systems.
Bruker Daltonics claims that maXis is already well proven as an exceptional tool in quantitative proteomics, peptide and intact protein analysis in addition to small molecule identification using the unique SmartFormula™ 3D method for on-the-fly unambiguous molecular formula read-out, as co-developed with Pfizer, UK.
Professor Richard Caprioli of the Vanderbilt University School of Medicine plans to use the maXis in his research on changes in protein expression in various disease states.
Prof. Caprioli commented: “The performance of the maXis in our laboratory after the installation has shown that we will be able to achieve new levels of confidence in protein identification, and quantification of changes in protein expressions levels, as well as those for drugs and metabolites. We see this instrument as highly complementary to our extensive research program in profiling changes in protein expression levels using MALDI-TOF imaging.”
At PITTCON 2009, Professor Jonathan V. Sweedler from the University of Illinois at Urbana will present maXis data demonstrating the ability to characterize neuropeptides in samples as small as a single neuron with an unprecedented combination of very high resolution, high sensitivity and tandem MS capabilities.
BioAscent Establishes Integrated Drug Discovery Services OfferingNews
Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.READ MORE
Lab Innovations returns to the NEC, Bimingham , UKNews
Save the date for the UK’s only lab-dedicated exhibition showcase!READ MORE
A Breath Test for Early Diagnosis of Oesophageal and Gastric CancerNews
In a multi-centre clinical trial of 335 patients, a new breath test can identify oesophageal and gastric cancer from benign diseases with 85 per cent accuracy. Unlike other methods, the test is non-invasive.READ MORE
Comments | 0 ADD COMMENT
International Conference on Biobetters and Regulatory Affairs
Jun 27 - Jun 28, 2018